Key result
Spironolactone plus an ACEi or ARB is linked to increased hyperkalaemia risk in heart failure.
Why the study?
Spironolactone use in heart failure patients combined with ACE inhibitors or AT2 antagonists is associated with hyperkalaemia risk, but real-world safety data are needed.
Does spironolactone combined with an ACE inhibitor or AT2 antagonist increase the risk of hyperkalaemia and drug withdrawal in patients with heart failure?
Observational
Does spironolactone combined with an ACE inhibitor or AT2 antagonist increase the risk of hyperkalaemia and drug withdrawal in patients with heart failure?
Real-world use of spironolactone with ACE inhibitors or ARBs in heart failure patients carries a higher risk of hyperkalemia and drug withdrawal than observed in clinical trials, particularly in patients with diabetes or low hematocrit.
Answers are grounded in this paper and cite their sources.
Supports closer K+ monitoring with spironolactone plus ACEi/ARB in real-world HF, especially diabetes or low hematocrit; leaves causal magnitude open for RCTs.
INTRODUCTION: Spironolactone is increasingly being used in the treatment of heart failure. However, it has been associated with cases of hyperkalaemia. The common use of angiotensin-converting enzyme (ACE) inhibitors and angiotensin-2 receptor (AT2) antagonists in heart failure increases the risk of hyperkalaemia. OBJECTIVE: To identify the risk of spironolactone withdrawal, hyperkalaemia and severe hyperkalaemia in patients prescribed spironolactone together with either an ACE inhibitor or an AT2 antagonist. METHODS: Retrospective identification and analysis of patients co-prescribed an ACE inhibitor or an AT2 antagonist with spironolactone. Patients' records were linked to their biochemical results and the doses of spironolactone, ACE inhibitor and AT2 antagonists received by them. RESULTS: We found that a higher proportion of patients in our cohort stopped taking spironolactone compared with the Randomised Aldactone Evaluation Study and a higher proportion developed hyperkalaemia, a predicted adverse effect of spironolactone combination with an ACE inhibitor or an AT2 antagonist. Patients with diabetes mellitus and those with a haematocrit below 0.36, were more likely to develop hyperkalaemia than those without these traits. CONCLUSIONS: Spironolactone is a common cause of hyperkalaemia when used in combination with either an ACE inhibitor or an AT2 antagonist. This reinforces the need for care when extrapolating the results of clinical trials to daily clinical practice.
No takes yet. Share an insight, caveat, or question.
Cox et al. (2003) conducted an observational in Heart failure. Spironolactone co-prescribed with an ACE inhibitor or AT2 antagonist was evaluated on Spironolactone withdrawal, hyperkalaemia, and severe hyperkalaemia. Co-prescription of spironolactone with an ACE inhibitor or AT2 antagonist in heart failure patients increased hyperkalaemia risk, especially with diabetes or haematocrit <0.36.
Synapse has enriched 10 related papers. Consider them for comparative context: